A01K 2267/0331
Animal model for proliferative diseases
A01K2267/0331 (Animal model for proliferative diseases) appears on 639 US grants and 1,221 published applications in this corpus.
Search patents in A01K- Granted patents
- 639
- Published applications
- 1,221
- Assignees
- 587
- Inventors
- 2,459
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 3 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 8 | 0 |
| 1997 | 4 | 0 |
| 1998 | 6 | 0 |
| 1999 | 17 | 0 |
| 2000 | 8 | 0 |
| 2001 | 15 | 3 |
| 2002 | 9 | 35 |
| 2003 | 16 | 40 |
| 2004 | 15 | 35 |
| 2005 | 15 | 41 |
| 2006 | 20 | 56 |
| 2007 | 21 | 60 |
| 2008 | 14 | 55 |
| 2009 | 25 | 54 |
| 2010 | 24 | 46 |
| 2011 | 14 | 38 |
| 2012 | 24 | 30 |
| 2013 | 28 | 31 |
| 2014 | 9 | 27 |
| 2015 | 21 | 40 |
| 2016 | 20 | 46 |
| 2017 | 24 | 35 |
| 2018 | 22 | 47 |
| 2019 | 26 | 76 |
| 2020 | 19 | 76 |
| 2021 | 40 | 81 |
| 2022 | 31 | 88 |
| 2023 | 40 | 57 |
| 2024 | 34 | 60 |
| 2025 | 38 | 41 |
| 2026 | 28 | 23 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Genetically modified non-human animal with human or chimeric TFR122 Sep 2026US 12,740,550 B2Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Non-canonical SWI/SNF complex and uses thereof8 Sep 2026US 12,729,225 B2Dana-Farber Cancer Institute, Inc.
- Anti-CD22 single domain antibodies and therapeutic constructs11 Aug 2026US 12,703,744 B2National Research Council of Canada
- Genetically modified mice having a humanized programmed cell death 1 gene14 Jul 2026US 12,677,813 B2Regeneron Pharmaceuticals, Inc.
- Genetically modified non-human animals and methods of use thereof7 Jul 2026US 12,672,643 B2Institute for Research in Biomedicine (IRB)
- Genetically Modified Non-Human Animals and Methods of Use Thereof8 Oct 2026US 2026/0305588 A1Institute for Research in Biomedicine (IRB)
- Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse8 Oct 2026US 2026/0308532 A1Fred Hutchinson Cancer Center
- Use of inhibitors of adam12 as adjuvants in tumor therapies24 Sep 2026US 2026/0286009 A1Institut National de la Sante et de la Recherche Medicale
- Nf2-associated meningioma model24 Sep 2026US 2026/0286314 A1
- Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies20 Aug 2026US 2026/0242801 A1ImmunityBio, Inc.
Most cited
By later US patents
- Transgenic non-human mammals531US 4,736,866 APresident and Fellows of Harvard College · 1988
- Cysteine engineered antibodies and conjugates485US 7,521,541 B2Genetech, Inc. · 2009
- Methods of treatment using anti-ErbB antibody-maytansinoid conjugates152US 7,097,840 B2Genentech, Inc. · 2006
- Cysteine engineered antibodies and conjugates149US 7,855,275 B2Genentech, Inc. · 2010
- Antisense composition and method for treating cancer126US 7,402,574 B2AVI BioPharma, Inc. · 2008